AngioDynamics Inc. (ANGO) is a leading global medical device company committed to providing innovative, minimally invasive solutions for physicians and patients worldwide. The company was founded in 1988, with its headquarters in New York, United States. In the three decades since its founding, AngioDynamics has established a robust reputation for developing innovative and effective medical technologies that enhance patient outcomes and provide cost-efficient solutions to medical professionals.
AngioDynamics Inc. operates through three primary business segments: Vascular Interventions & Therapies (VIT), Oncology, and Vascular Access (VA). Each division focuses on specific areas of care, ensuring the company stays ahead of the curve in its innovative specialties. The company’s VIT offering includes groundbreaking devices like AngioVac, a powerful system for removing harmful material like clots from blood vessels. In the oncology segment, the company is a pioneer in the development of therapies such as NanoKnife, which uses electric currents to destroy hard-to-reach or inoperable tumors.
The company's reputation in the medical industry is firmly rooted in its steadfast commitment to serving patients. Their products are designed to ensure patient safety, improve outcomes, and reduce the total cost of care. The patient-first approach has been central to their manifold achievements in improving both patient outcomes and the efficacy of the physicians and medical staff who use their products.
Moreover, AngioDynamics is recognized for its deep commitment to R&D, as evidenced by a robust pipeline of products. It is dedicated to constant product innovation, aiming to improve the quality of patient care and offer cost-saving solutions for healthcare providers. Beyond the medical benefits, their products are intuitively designed with clinicians in mind, ensuring that they are easy to use, saving time, and reducing stress for healthcare providers.
The company is listed on the NASDAQ Stock Exchange under the symbol ANGO. It stands firmly focused on innovation, patient outcomes, and physician efficiency, with ethics and integrity vitally integral to its operation. Its dedication to creating state-of-the-art medical devices that enhance patient care while maximizing efficiency for medical professionals has positioned AngioDynamics Inc. as a leader in the global medical device industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
AngioDynamics, Inc. announced inducement grants to Eric Honroth in connection with his appointment as Chief Executive Officer, effective November 2, 2026. These awards include time-based and performance-based restricted stock units, granted under Nasdaq Listing Rule 5635(c)(4) and approved by the independent Compensation Committee. The awards will vest over specified periods, subject to Mr. Honroth's continued service and the achievement of performance metrics for the performance-based units.
A Texas woman has filed a product liability lawsuit against AngioDynamics Inc. and Navilyst Medical Inc., alleging that a defective SmartPort port catheter caused her to develop a candida fungal bloodstream infection. The lawsuit claims the companies manufactured and marketed implants with inferior materials, leading to the device fracturing and causing severe health issues, including a 16-day hospitalization for sepsis and other complications. This case is part of a growing number of port catheter lawsuits, with similar federal claims consolidated in multidistrict litigations.
AngioDynamics reported a 6.9% increase in Q1 FY2027 revenue to $80.9 million, driven by a 13.2% rise in its Med Tech segment. Key growth drivers included the Auryon and NanoKnife platforms, with record prostate procedure volumes for NanoKnife. The company maintained its full-year guidance and announced a leadership transition, with Eric Honroth succeeding James Clemmer as President and CEO.